Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial
NCT ID: NCT07264686
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
222 participants
INTERVENTIONAL
2025-11-03
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG
NCT06690814
Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot
NCT03209466
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
NCT02394821
Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers
NCT01913704
SALACIA: SALvesAn vs Conventional Management of dIAbetic Foot Wounds
NCT06908148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
(A) Pterocarpus indicus plant sap (50μl) applied topically at baseline and for four more days (B) Savlon cream (200mg) applied topically at baseline and for four more days (C) No treatment
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ficus septica exudate
Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
Ficus septica exudate
Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Common over the counter antiseptic cream
Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Control
no intevention control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ficus septica exudate
Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Accepted and signed informed consent by a legal guardian (relative or teacher)
* Ability and willingness to comply with the requirements of the study protocol including follow up visits.
Exclusion Criteria
* Ulcer presenting with a crust (not predominantly moist surface), or dimensions different to those specified in point 1 above.
* Refusal at ward level or village chief (for village inclusion), or refusal of individual or guardian (for individual inclusion).
* Answered yes when asked if had taken antibiotics in the last week or presents with visible signs of ulcer treatment e.g. wound dressing.
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Royal Botanic Gardens, Kew
UNKNOWN
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vunapope Hospital, and surrounding area
Kokopo, EAST NEW Britan, Papua New Guinea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UlcerPlants2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.